SCHEMBL13329976

SCHEMBL13329976

COc1cc(C)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.42
ADRA2C P18825 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
CYP1A1 P04798 1/20 0.40
CYP3A4 P08684 4/20 0.39
ERBB2 P04626 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39
ERAP1 Q9NZ08 1/20 0.39
ALPL P05186 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350724 0.82 NAPRT (0.43) CYP1A1CYP3A4ERBB2KDM4EALDH1A1
SCHEMBL2363082 0.82 HTR2A (0.44) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2363467 0.82 CYP3A4 (0.43) CYP1A1CYP3A4ERBB2ALPLKDM4E
SCHEMBL2349673 0.81 CYP1A1 (0.37) CYP1A1CYP3A4ERBB2NPC1RAB9A
SCHEMBL3308904 0.80 CYP3A4 (0.42) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2362488 0.80 HTR2A (0.54) CYP1A1CYP3A4
SCHEMBL2362428 0.80 CYP3A4 (0.44) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2354432 0.80 KDM4E (0.40) CYP3A4NPC1RAB9AKDM4EALDH1A1
SCHEMBL1543223 0.80 CYP3A4 (0.47) CYP1A1CYP3A4ERBB2ALPLKDM4E
SCHEMBL3316087 0.79 MAP4K1 (0.38) CYP1A1CYP3A4ERBB2ALPLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B ADRA2A 1948/4885ADRA2C 1312/4885ADRA1D 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.